GlobeNewswire·Nov 12, 2026, 6:30 AM ET

Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates

EIKN

Presented seven posters at the 2026 ESMO Congress covering clinical data for EIK1001, PARP1-selective inhibitors, WRN helicase inhibitors, and updated EIK1001 results from the TeLuRide-005 Phase 2 NSCLC trial
Dosed the first patient in TeLuRide-008, a registrational Phase 2/3 trial of EIK1001 combined with pembrolizumab & chemotherapy for stage 4 NSCLC
Submitted an Investigational New Drug application for EIK1006, a non-lutamide androgen receptor antagonist targeting prostate cancer variants
Appointed Ching-Pin Chang, M.D., Ph.D., as Chief Scientific Officer
Ended the third quarter of 2026 with $461.7 million in cash, cash equivalents, & marketable securities, extending runway guidance to the first quarter of 2028
Reported TeLuRide-005 results showing a 63.1% objective response rate in the pooled population, with 72.4% in the squamous cohort & 55.6% in the non-squamous cohort
Reported initial data for EIK1003 showing a 14.3% overall objective response rate in monotherapy & a 20.8% rate in combination with abiraterone for prostate cancer
Reported initial data for EIK1004 showing a 12.1% objective response rate & 62.1% disease control rate across breast, ovarian, & prostate cancers
Reported preliminary EIK1005 data showing stable disease in 6 of 8 participants with MSI-high tumors & a partial response in the first combination therapy patient
Reported third-quarter 2026 net loss of $86.1 million, with R&D expenses of $71.8 million & G&A expenses of $18.7 million
Scheduled key milestones for 2027, including interim analyses for EIK1001 trials & initial results for EIK1003, EIK1004, EIK1005, & EIK1006

Company: Eikon Therapeutics, Inc.
Keywords: Nasdaq:EIKN, Eikon Therapeutics, Inc.